Infections in patients with hematological cancer: recent developments
- PMID: 14633794
- DOI: 10.1182/asheducation-2003.1.438
Infections in patients with hematological cancer: recent developments
Abstract
One of the most common complications involved in treating patients with hematologic cancer is infection. In many cases there are multiple factors that predispose these patients to infections such as neutropenia induced by therapy or bone marrow involvement, hypogammaglobulinemia, T-cell dysfunction, and mucosal damage. In addition, newer therapies have changed the spectrum of infection that is seen in these patients. In Section I, Dr. Blijlevens discusses mucosal damage as a major risk factor for complications of cytotoxic chemotherapy. She focuses on mucosal barrier injury (MBI) as manifest in the GI tract and will describe a pathological model to explain MBI, evaluate risk factors for development of this syndrome, explain the relationship between MBI and infection, and discuss treatment and prevention of this injury. Invasive fungal infections continue to represent a significant problem in patients with hematologic cancer. In Section II, Drs. Anaissie and Mahfouz review the latest developments in the diagnosis, prevention, and management of invasive fungal infections with a focus on a risk-adjusted approach to this problem. Finally, in Section III, Dr. O'Brien reviews infections associated with newer therapeutic regimens in hematologic cancers. The spectrum of infections has changed with the use of purine analogs and the advent of monoclonal antibodies. The profound T-cell suppression associated with these therapies has led to the emergence of previously rare infections such as cytomegalovirus. An approach to both prophylaxis and management of these infections is discussed.
Similar articles
-
Management of mycoses in patients with hematologic disease and cancer -- review of the literature.Eur J Med Res. 2002 May 31;7(5):227-35. Eur J Med Res. 2002. PMID: 12069913 Review.
-
Treatment of systemic fungal infections in patients with hematologic malignancies.Antibiot Chemother (1971). 2000;50:79-93. doi: 10.1159/000059318. Antibiot Chemother (1971). 2000. PMID: 10874457 Review. No abstract available.
-
[Mycoses and their treatment in malignant hemopathies].Recenti Prog Med. 1999 Mar;90(3):160-8. Recenti Prog Med. 1999. PMID: 10228357 Review. Italian.
-
[Pocket guide to invasive mycoses in onco-hematologic patients].Rev Iberoam Micol. 2009;Suppl:3-199. Rev Iberoam Micol. 2009. PMID: 20143497 Spanish. No abstract available.
-
Meta-Analysis and Cost Comparison of Empirical versus Pre-Emptive Antifungal Strategies in Hematologic Malignancy Patients with High-Risk Febrile Neutropenia.PLoS One. 2015 Nov 10;10(11):e0140930. doi: 10.1371/journal.pone.0140930. eCollection 2015. PLoS One. 2015. PMID: 26554923 Free PMC article. Review.
Cited by
-
New thoughts on the pathobiology of regimen-related mucosal injury.Support Care Cancer. 2006 Jun;14(6):516-8. doi: 10.1007/s00520-006-0058-1. Epub 2006 Apr 1. Support Care Cancer. 2006. PMID: 16583189 Review.
-
Religious beliefs and cancer screening behaviors among Catholic Latinos: implications for faith-based interventions.J Health Care Poor Underserved. 2014 May;25(2):503-26. doi: 10.1353/hpu.2014.0080. J Health Care Poor Underserved. 2014. PMID: 24858865 Free PMC article.
-
Should treatment of hypogammaglobulinemia with immunoglobulin replacement therapy (IgRT) become standard of care in patients with chronic lymphocytic leukemia?Front Immunol. 2023 Apr 14;14:1062376. doi: 10.3389/fimmu.2023.1062376. eCollection 2023. Front Immunol. 2023. PMID: 37122737 Free PMC article. Review.
-
Challenges in the Role of Gammaglobulin Replacement Therapy and Vaccination Strategies for Hematological Malignancy.Front Immunol. 2016 Aug 22;7:317. doi: 10.3389/fimmu.2016.00317. eCollection 2016. Front Immunol. 2016. PMID: 27597852 Free PMC article. Review.
-
Development of an orogastrointestinal mucosal model of candidiasis with dissemination to visceral organs.Antimicrob Agents Chemother. 2006 Aug;50(8):2650-7. doi: 10.1128/AAC.00530-06. Antimicrob Agents Chemother. 2006. PMID: 16870754 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources